



The glycine *N*-acyltransferases, GLYAT and GLYATL1, contribute to the detoxification of isovaleryl-CoA - an *in-silico* and *in vitro* validation



Stefan Kühn^a, Monray E. Williams^a, Marli Dercksen^a, Jörn Oliver Sass^b, Rencia van der Sluis^{a,*}

^a Focus Area for Human Metabolomics, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa

^b Research Group Inborn Errors of Metabolism, Institute for Functional Gene Analytics, Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, von-Liebig-Str. 20, 53359 Rheinbach, Germany

ARTICLE INFO

Article history:

Received 15 November 2022

Received in revised form 27 January 2023

Accepted 29 January 2023

Available online 31 January 2023

Keywords:

Isovaleric acidemia
Glycine *N*-acyltransferase
Glycine conjugation
N-isovalerylglycine

ABSTRACT

Isovaleric acidemia (IVA), due to isovaleryl-CoA dehydrogenase (IVD) deficiency, results in the accumulation of isovaleryl-CoA, isovaleric acid and secondary metabolites. The increase in these metabolites decreases mitochondrial energy production and increases oxidative stress. This contributes to the neuropathological features of IVA. A general assumption in the literature exists that glycine *N*-acyltransferase (GLYAT) plays a role in alleviating the symptoms experienced by IVA patients through the formation of *N*-isovalerylglycine. GLYAT forms part of the phase II glycine conjugation pathway in the liver and detoxifies excess acyl-CoA's namely benzoyl-CoA. However, very few studies support GLYAT as the enzyme that conjugates isovaleryl-CoA to glycine. Furthermore, GLYATL1, a paralogue of GLYAT, conjugates phenylacetyl-CoA to glutamine. Therefore, GLYATL1 might also be a candidate for the formation of *N*-isovalerylglycine. Based on the findings from the literature review, we proposed that GLYAT or GLYATL1 can form *N*-isovalerylglycine in IVA patients. To test this hypothesis, we performed an *in-silico* analysis to determine which enzyme is more likely to conjugate isovaleryl-CoA with glycine using AutoDock Vina. Thereafter, we performed *in vitro* validation using purified enzyme preparations. The *in-silico* and *in vitro* findings suggested that both enzymes could form *N*-isovalerylglycine albeit at lower affinities than their preferred substrates. Furthermore, an increase in glycine concentration does not result in an increase in *N*-isovalerylglycine formation. The results from the critical literature appraisal, *in-silico*, and *in vitro* validation, suggest the importance of further investigating the reaction kinetics and binding behaviors between these substrates and enzymes in understanding the pathophysiology of IVA.

© 2023 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Isovaleric acidemia (IVA, OMIM: 243500) is a rare autosomal inherited recessive disorder first identified by Tanaka and Isselbacher (1967). The incidence of IVA is 1 in 250 000 in the USA [1,2] and 1 in 526 000 in other Western populations [3]. In Germany, newborn screening (NBS) data collected between 2004 and 2017 showed a birth prevalence for IVA of 1 in 94 000 newborns [4]. In South Africa (ZA), no official statistics on the prevalence or incidence

have been published. However, 15 patients have been diagnosed by the Centre for Human Metabolomics (CHM) at North-West University (NWU). In developing countries, such as ZA, NBS are typically accessed by the private sector, which accounts for the low incidence of IVA in these countries as only 6000 out of 1 000 000 births are screened [5].

IVA arises from a defect in isovaleryl-CoA dehydrogenase (IVD, E.C. 1.3.8.4) that leads to a defective catabolism of the branched chain amino acid, leucine [6]. IVD is mainly expressed in the thyroid, liver, and kidney (Data taken from NCBI – accessed 24 April 2022) and catalyzes the conversion of isovaleryl-CoA to 3-methylcrotonyl-CoA. An IVD enzyme defect results in the accumulation of various metabolites which are then shunted towards several secondary metabolic pathways including glycine conjugation. 3-Hydroxyisovaleric acid, *N*-isovalerylglycine and *N*-isovalerylcarnitine are

* Corresponding author.

E-mail addresses: 44926324@mynwu.ac.za (S. Kühn),

Monray.Williams@nwu.ac.za (M.E. Williams),

Marli.Dercksen@nwu.ac.za (M. Dercksen), jorn.oliver.sass@h-brs.de (J.O. Sass),

21224919@nwu.ac.za (R. van der Sluis).

utilized as primary biomarkers [7] in the diagnosis of IVA. Additionally, the accumulation of isovaleryl-CoA results in sequestration of CoA and formation of large amounts of isovaleric acid [8].

According to the proposed standard classification, IVA patients may fall within two phenotypic groups namely: the acute neonatal form and chronic intermittent form [9]. The acute neonatal form is characterized by encephalopathy, developmental delay, lethargy, and a sweaty feet odor. Mild neurocognitive and motor deficits are characteristic of the intermittent IVA form and is typically triggered by stresses such as infection, fever, a high-protein diet or extensive fasting [10]. With the expansion of NBS programs, an asymptomatic to mild phenotype of IVA has also been identified [11]. This emphasizes the importance of biochemical characterization and monitoring of patients to determine the degree of intervention required to assure optimal outcome [9,10,12,13].

The underlying pathophysiology that leads to cerebral damage in these patients, is still not fully elucidated. Studies in rats indicate that metabolites which accumulate during IVA can induce oxidative stress in the cerebral cortex and that oxidative damage may be at least in part involved in the neuropathology of IVA [14]. Additionally, free isovaleric acid can reduce Na⁺, K⁺-ATPase activity in the synaptic membranes of cerebral cortexes of young rats, possibly via mechanisms involving lipid peroxidation [15]. Furthermore, hyperammonemic encephalopathy is a common feature in untreated/poorly managed patients as isovaleryl-CoA has an inhibitory effect on *N*-acetylglutamate synthase activity resulting in poor ammonia clearance via the urea cycle pathway [16]. The repercussion of this is irreversible central nervous damage because of accumulating ammonia acting as a neurotoxin. *N*-carbamylglutamate is an approved pharmacological agent for the treatment of acute and chronic hyperammonemia in IVA [17].

The haplotype frequency data for IVD available on the Ensembl database show that the reference haplotype is found at a frequency of 98.3% in the worldwide population while the remainder of the haplotypes have haplotype frequencies ranging from 0.02% to 1% (Data taken from Ensembl.org; accessed 19 Apr 2022 for transcript ENST00000487418.8 - Canonical transcript with TSL 1 score). This indicates that the *IVD* gene is highly conserved and that mutations are found at very low frequencies. Molecular analysis of the *IVD* gene has allowed for the identification of different types of pathogenic variants, with no straightforward phenotype–genotype correlation in most cases [10,11]. Although a recent study recommends that additional investigations may be required to conclusively define if genotype–phenotype correlations can be made in some IVA populations [18]. The most common IVD mutation (c.932 C > T, p.A282V) results in a lower affinity for isovaleryl-CoA as well as a reduced catalytic efficiency and is associated with a mild biochemical, but clinical asymptomatic phenotype [4,11]. The ZA Caucasian cohort are all homozygous for the same (c.367 G > A, p.G123R) mutation [13], which results in no protein expression or detectable IVD activity.

1.1. Treatment strategies for IVA

Presently there are three modes of treatment for IVA: prevention of metabolic decompensation by careful clinical observation, long term reduction of the production of isovaleryl-CoA through dietary manipulation, and activation of secondary metabolism by shunting isovaleryl-CoA towards reactions that produce non-toxic metabolites [7,19]. These treatments, if applied timely, generally results in normal neurological development [13,20–22], while motor dysfunction and neurological deficits have mostly been observed with delayed therapeutic intervention [9]. Interestingly, the same group emphasized that the neurocognitive outcome is not related to the catabolic episodes, and that further investigations are required to assess clinical heterogeneity. For this study, the focus will be on one

of the secondary metabolic pathways involved in the third mode of treatment, namely glycine conjugation.

N-isovalerylglycine was identified in the urine of IVA patients by Tanaka and Isselbacher (1967). Isovaleryl-CoA, produced by oxidation of leucine through α -ketoisocaproic acid, cannot be utilized by primary metabolic pathways such as the citric acid cycle or β -oxidation. Under these circumstances, the conjugation of isovaleryl-CoA with glycine permits detoxication and elimination of accumulated isovaleryl-CoA as *N*-isovalerylglycine. This mechanism might be adequate to protect patients from the accumulation of isovaleric acid in the blood and other body fluids, which led to the use of glycine as treatment [23]. As a result, a clear clinical improvement was observed in IVA patients [24]. Unfortunately, as a result of the clinical variation of IVA, its rarity, and the lack of extensive, multi-center, longitudinal studies on patient outcomes, there is no consensus regarding optimal dietary management and the combined or singular use of glycine and L-carnitine for detoxification purposes [9,25]. L-carnitine treatment decreases free isovaleric acid levels during acute metabolic decompensation [26].

Even though glycine is recommended as a treatment for IVA, several studies have reported adverse events in some patients [27–29]. A recent publication by Vliet et al. indicated that glycine supplementation should be carefully considered in a patient-to-patient basis [25]. This is since hyperglycinemia (in case of excess systemic glycine moving over the blood brain barrier) may result in acquired encephalopathy detrimental to the patient.

Tanaka and Isselbacher were the first to suggest that glycine *N*-acyltransferase (GLYAT, EC 2.3.1.13) might be the enzyme responsible for the formation of *N*-isovalerylglycine [23]. Even though Tanaka and Isselbacher referred to a study on bovine GLYAT [30], the literature states that human GLYAT can conjugate isovaleryl-CoA to glycine [13,31,32]. However, is there any evidence that human GLYAT is indeed responsible for the formation of *N*-isovalerylglycine?

1.2. The glycine conjugation pathway

The glycine conjugation pathway is a two-step enzymatic reaction responsible for the detoxification of various substrates (Fig. 1) [23,32–36]. The mitochondrial xenobiotic/medium chain fatty acid: CoA ligases (ACSM2B, EC 6.2.1.2) activate substrates, such as benzoate, to an acyl-CoA [37,38]. The acyl-CoA's are then subsequently conjugated to glycine by GLYAT [23,30,39]. The glycine conjugation pathway also plays a fundamental role in the homeostatic energy balance within the mitochondria by regenerating the CoA moiety [40].




Fig. 1. An overview of the glycine conjugation pathway and the substrates that it detoxifies. 1 & 2: Benzoate and salicylate (food, medicine and preservatives) are activated to an acyl-CoA by the mitochondrial xenobiotic/medium chain fatty acid: CoA ligase (ACSM2B) and subsequently conjugated to glycine by glycine *N*-acyltransferase (GLYAT). 3. Gut microorganisms convert dietary polyphenols to benzoyl-CoA, which is a substrate for glycine conjugation. 4. MCFAs, example caprylic acid, are activated by ACSM2B ligase in the liver before entering the mitochondrial beta-oxidation cycle.

Table 1
Summary of studies that evaluated the ability of human GLYAT to conjugate isovaleryl-CoA to glycine.

Enzyme preparation	CoA substrates evaluated	Amino acid substrates evaluated	Formation of <i>N</i> -isovalerylglycine	Reference
Enzyme extract from human liver and kidney tissue	phenylacetyl-CoA benzoyl-CoA isobutyryl-CoA isovaleryl-CoA indolyl acetyl-CoA p-hydroxyphenylacetyl-CoA	glycine glutamine	No	[41]
Human liver lysate	2-methyl butyryl-CoA isobutyryl-CoA butyryl-CoA hexanoyl-CoA octanoyl-CoA decanoyl-CoA isovaleryl-CoA	glycine	<i>N</i> -isovalerylglycine formed under experimental conditions not comparable to physiological conditions	[42]
Enzyme preparation isolated from human liver	benzoyl-CoA butyryl-CoA salicylyl-CoA heptanoyl-CoA isovaleryl-CoA	glycine	isovaleryl-CoA had the lowest substrate specificity	[43]

1.2.1. Glycine conjugation in IVA

Only three experimental studies (Table 1) are available that attempted to show that human GLYAT can conjugate isovaleryl-CoA with glycine [41–43].

In the first study, an enzyme extract from human liver and kidney tissue was used to test the conjugation of phenylacetyl-CoA, benzoyl-CoA, isobutyryl-CoA, isovaleryl-CoA, indolyl acetyl-CoA and p-hydroxyphenylacetyl-CoA with either glutamine or glycine. Although this enzyme preparation catalyzed the formation of hippuric acid (benzoylglycine), no evidence for the conjugation of isovaleryl-CoA to glycine could be found in either the liver or kidney [41].

Subsequently, Gregersen et al., prepared a human liver lysate and developed a GC/MS assay to determine GLYAT affinity for 2-methyl butyryl-CoA, isobutyryl-CoA, butyryl-CoA, hexanoyl-CoA, octanoyl-CoA, decanoyl-CoA and isovaleryl-CoA [42]. *N*-isovalerylglycine was quantified in this study, but the substrate concentrations used for isovaleryl-CoA (672 μ M) and glycine (523 mM) were very high and are not comparable to intracellular substrate concentrations. For example, in nonketotic hyperglycinemia, intracellular glycine concentration in brain tissue do not exceed 30 mM, while the glycine concentration in the liver is approximately 5 mM [44,45].

The last study determined the substrate specificity of an enzyme preparation isolated from human liver. The highest activity was obtained with benzoyl-CoA which was set as the maximum relative activity of 100%. This was followed by butyryl-CoA (28%), salicylyl-CoA (22%), heptanoyl-CoA (9.5%) and isovaleryl-CoA (9.1%) [43].

While all three studies could show conjugation between acyl-CoA substrates and amino acids, the enzyme preparations were neither homogenous nor purified. In other words, the extracts contained other mitochondrial enzymes. None of the studies could show that isovaleryl-CoA is a good substrate for GLYAT. This is puzzling when one considers that during an IVA episode, patients can excrete up to 1700 mg of *N*-isovalerylglycine per day, while [23], hippurate (the conjugate formed by the preferred substrates benzoyl-CoA and glycine), is only excreted to a maximum of 716 mg per day [46]. Therefore, if isovaleryl-CoA is indeed a poor substrate for GLYAT, how is *N*-isovalerylglycine then excreted at significantly greater quantities than the preferred substrate? We propose that a greater understanding of the kinetic and docking behavior of the GLYAT enzymes may yield an answer to this question.

Although these three studies (Table 1) could not show that isovaleryl-CoA is a good substrate for human GLYAT, the use of crude preparations may confound these findings. Kelley and Vessey (1994) for example analyzed GLYAT substrate specificity using an enzyme

preparation with three distinct proteins. Furthermore, a homologous gene, *GLYATL1*, is located on human 11q12.1 which [47] has 39% nucleotide identity to GLYAT. *GLYATL1* is a glutamine *N*-acyl-transferase enzyme present in the mitochondrial fractions from human kidney and liver. [41,48]. This then raises the question whether an enzyme with a preference for ι -glutamine can also conjugate isovaleryl-CoA to glycine? Previous studies have shown that *GLYATL1* can conjugate benzoyl-CoA (0.027 U/mg protein) and phenylacetyl-CoA (0.085 U/mg protein) to glycine, albeit at lower rates, when compared to the glutamine conjugation rates (0.101 and 0.603 U/mg enzyme respectively) [41,48]. Moldave and Meister, however, could not obtain evidence for *GLYATL1* of *N*-isovalerylglycine formation from isovaleryl-CoA and glycine [41].

It is also important to distinguish between the studies done on human GLYAT [41–43] and those done on bovine GLYAT [30,32] as the kinetic mechanisms of these two enzymes are different. Human GLYAT exhibits sigmoidal kinetics [49] whereas bovine GLYAT follow Michaelis-Menten kinetics [50]. Sigmoidal enzymes do not follow a hyperbolic curve, but a sigmoidal one *i.e.* the observed kinetic behaviour is a consequence of co-operativity in the substrates binding [51]. In the case of human GLYAT, the cooperativity is stronger for benzoyl-CoA than for glycine [52]. If the preferred substrate for GLYAT, benzoyl-CoA, outcompetes isovaleryl-CoA for conjugation to glycine this can impact the efficacy of treating IVA with glycine supplementation. However, this would require further study.

To date, no study has shown that a purified GLYAT enzyme can conjugate isovaleryl-CoA to glycine. It is important to verify whether the assumption that GLYAT can conjugate isovaleryl-CoA to glycine is indeed correct. Especially since in the ZA cohort of IVA patients who are all homozygous for the same IVD mutation, variation in the responsiveness to glycine supplementation was observed [13]. This variation might be due to several factors. Firstly, variants in GLYAT as well as transcriptional regulation of GLYAT, may affect enzyme activity. Secondly, substrate competition between isovaleryl-CoA and other, more preferred substrates might result in the preferred substrate outcompeting isovaleryl-CoA. Thirdly, there may be inhibitors, regulators, or interactions with other enzymes that can affect the variation in *N*-isovalerylglycine formation.

No studies are available on the interaction or putative competition between the various acyl-CoA substrates involved in the glycine conjugation pathway. One study did show that ι -carnitine conjugation to isovaleryl-CoA occurs earlier than isovaleryl-CoA conjugation to glycine [26], which might indicate that the conjugation of isovaleryl-CoA is delayed by the competition of other substrates.

Improving our understanding of the pathophysiology of IVA, specifically the activation of secondary metabolic pathways, such as glycine conjugation, in response to increased isovaleryl-CoA accumulation, is required to optimize the monitoring of diagnosed IVA patients and to potentially improve, even personalise current treatment strategies. The potential of an acquired hyperglycinemia makes this study even more important as an understanding of the capacity of the glycine conjugation pathway to form *N*-isovalerylglycine may further contribute to realistic treatment recommendations. Therefore, the aim of this study is to test the hypothesis whether GLYAT and/or GLYATL1 can conjugate isovaleryl-CoA to glycine. Firstly, molecular modelling and binding interactions of the proposed enzymes (GLYAT and GLYATL1) and substrates (isovaleryl-CoA and glycine) were done to establish which of the enzymes are more likely to bind isovaleryl-CoA to glycine. The results of the *in-silico* analyses were then validated by analyzing various enzyme reactions using recombinantly expressed purified enzymes.

2. Methods

2.1. Retrieval of GLYAT and GLYATL1 enzyme sequences and substrate structures

The GLYAT (S_{156} GLYAT variant; WT Ref seq NM_201648.3) and GLYATL1 (WT ref Seq NM_001389712.2) sequences were obtained from Ensembl (ensembl.org/). The 3D structures of the substrates were retrieved from Protein Data Bank (PDB; <https://www.rcsb.org/>). Benzoyl-CoA (PDB: 4Z3Y), glycine (PDB: 3OWW), phenylacetyl-CoA (PDB: 4IIT), glutamine (PDB: 6QN3) and isovaleryl-CoA (PDB: 5K7H) were extracted from experimentally solved 3D structures (X-ray diffraction).

2.2. Secondary structure prediction

Secondary structure elements consisting of alpha-helices, beta-sheets, and random coils were predicted for GLYAT and GLYATL1 using the PSIPRED secondary structure prediction server3 (<http://bioinf.cs.ucl.ac.uk/psipred>) [53].

2.3. Prediction of disordered state of GLYAT and GLYATL1

The DISOPRED3 program was used for protein disorder prediction and protein-binding site annotation within disordered regions (<http://bioinf.cs.ucl.ac.uk/disopred>) [54]. The server allows users to submit a protein sequence and returns a probability estimate of each residue in the sequence being disordered. Briefly, the GLYAT and GLYATL1 protein sequences were uploaded to the database for residue disorder prediction. Here, we wanted to predict the prevalence of disordered states within GLYAT and GLYATL1 to infer their potential function. Proteins with a higher prevalence of disordered states do not always conform to the traditional “sequence-structure-function” paradigm [55] and therefore, the prediction of disordered states assists in the interpretation of findings from docking studies.

2.4. 3D structure prediction of GLYAT and GLYATL1 using SWISS-MODEL

SWISS-MODEL (<https://swissmodel.expasy.org/>) is a fully automated protein structure homology-modelling server [56,57] which was used to model GLYAT and GLYATL1. The GLYAT and GLYATL1 protein sequences were used as input to the SWISS-MODEL web interface. From the input sequence, SWISS-MODEL first performs a template search, then it selects and aligns the template. The aligned template is then used to build a model and lastly the model quality is assessed [56,57]. For the prediction of GLYAT, the template ID: 7pk1.1. A (sequence identity: 75.93% and coverage: 1.00) and for

GLYATL1, the template ID: 7pk1.1. A (sequence identity 41.30% and coverage: 0.97) were selected. The templates with the highest sequence identity and coverage to the target sequences were selected for model building. The SWISS-MODEL webserver reports inbuilt quality assessment scores for protein models predicted using the webserver, such as the Global Model Quality Estimate (GMQE) score [58]. The GMQE score gives an overall model quality measurement between 0 and 1, with higher numbers indicating higher accuracy of the model built with that specific alignment and template [58]. Where predicted models were missing residues, these were remodeled using previous modelled structures from the Alpha Fold protein structure database as templates (GLYA T: Q6IB77 and GLYATL1: Q969I3). The final predicted structures were subjected to protein 3D structure quality assessment.

2.5. 3D structure quality assessment

To assess the quality of the predicted 3D structures, a variety of structural parameters were tested within each model. Procheck, VERIFY3D and ERRAT from the Structural Analysis and Verification Server (SAVES)5 were used to evaluate the quality of the predicted structures. Procheck was used to determine if the predicted residues were within the allowable region of the Ramachandran plot [59]. Structures were considered reliable if more than 90% of the residues had favorable phi and psi dihedral angle distributions. The program VERIFY3D [60,61] measures the compatibility of a protein model with its own amino acid sequence. VERIFY3D produces an averaged 3D-1D score for each residue to evaluate the quality of the homology protein structure based on the energetic and empirical methods. Protein structures where more than 80% of the residues had a score greater than 0.2 are of high quality [62]. The program ERRAT [63] analyses the relative frequencies of noncovalent interactions between atoms of various types. ERRAT is considered the “overall quality factor” for non-bonded atomic interactions, with higher scores indicating higher quality. The generally accepted range is over 50 for a high-quality model [64]. ProSA-web-Protein Structure Analysis was used for the recognition of errors in three-dimensional structures of proteins and to measure total energy deviation within the protein structure [65]. This was used to determine whether the z-score of the input structure is within the range of scores typically found for native proteins of similar size. Lastly, the root mean square deviation (RMSD) values were calculated between the predicted structure and the homologous template structure using PYMOL/Maestro molecular visualizing software to compare backbone structural similarity to the experimentally solved template structure. Highly similar structures are considered when the RMSD is below 2 Å suggesting homology [66] whereas higher RMSD indicates that predicted structures and templates are not structurally similar. As a comparative analysis, we have also compared our structures to available structures on the Alpha Fold protein structure database for GLYAT (Q6IB77) and GLYATL1 (Q969I3). Protein structures that satisfy most or all of the quality parameter tests were considered reliable for subsequent docking studies.

2.6. Refinement and energy minimization

The predicted 3D structures were subsequently energy minimized using Modrefiner available at <https://zhanggroup.org/ModRefiner/>. Modrefiner refines protein structures from $C\alpha$ traces based on a two-step, atomic-level energy minimization [67]. Briefly, the predicted 3D structures for GLYAT and GLYATL1 were uploaded to the Modrefiner refinement interface. The final energy-minimized model was the lowest energy minima conformation of the protein structures, and these were utilized in molecular docking.

2.7. Molecular docking: AutoDock Vina

The molecular docking of the bi-substrates to GLYAT/GLYATL1 was carried out using AutoDock Vina [68], which is an open-source program for doing molecular docking. AutoDock Vina uses a sophisticated gradient optimization method in its local optimization procedure [68]. AutoDock Vina was used to determine binding affinities for several ligands to either GLYAT or GLYATL1. Preparatory steps, including preparation of pdbqt files for protein and ligands and grid box creation were completed using the Graphical User Interface program AutoDock Tools (ADT). Protein preparation included the removal of water molecules, the addition of polar hydrogens and united Kollman chargers. The grid size was set to $40 \times 40 \times 40$ xyz points with grid spacing of 0.375 Å. The grid center designated at dimensions (x, y, and z) differed with respect to each docking interaction. AutoDock Vina was employed for docking using protein and ligand information along with grid box properties in the configuration file. During the docking procedure, both the protein and ligands are considered rigid. AutoDock Vina generated 8 different docking poses. The pose with the lowest energy of binding or binding affinity was extracted and aligned with the receptor structure for further analysis. The preferred substrates for GLYAT are benzoyl-CoA and glycine [52,69] and for GLYATL1 it is phenylacetyl-CoA and glutamine [41]. Therefore, these were used as positive controls for our computational docking. Benzoyl-CoA binds to GLYAT first, followed by glycine [70]. Therefore, we docked GLYAT-benzoyl-CoA first, and this was sequentially followed by a second docking step to bind glycine. Similarly, we docked GLYATL1-phenylacetyl-CoA first, and this was sequentially followed by a second docking step to bind glutamine. Lastly, we docked isovaleryl-CoA to GLYAT and GLYATL1 respectively, and this was sequentially followed by a second docking step to bind glycine.

2.8. Protein–ligand interaction profiler

Protein–substrate interaction analysis was done using the protein–ligand interaction profiler (PLIP) [71]. Briefly, the docked complexes of GLYAT/GLYATL1 and substrates were uploaded to the PLIP webserver (<https://plip-tool.biotech.tu-dresden.de/plip-web/plip/index>). PLIP detects hydrogen bonds, hydrophobic contacts, π -stacking, π -cation interactions, salt bridges, water bridges, metal complexes, and halogen bonds between ligands and targets. Cut off for interactions formed were 4.1 Å for hydrogen bonds, 4.0 Å for hydrophobic contacts, 5.5 Å for π -stacking, 6.0 Å for π -cation interactions, 5.5 Å for salt bridges, 4.1 Å for water bridges, 3.0 Å for metal complexes, and 4.0 Å for halogen bonds.

2.9. Expression and purification of recombinant human GLYAT and GLYATL1

Glycerol stocks of C41(DE3)pLysS *E. coli* cells which contained either the pHis17_GLYAT or pET23a(+)_GLYATL1 plasmid were incubated in 20 mL of sterile media (2% m/v bacto-tryptone, 1.25% m/v yeast extract, 0.625% NaCl, 0.5% Na_2HPO_4 , 0.1% KH_2PO_4 , 0.2% m/v glucose, 100 $\mu\text{g}/\text{mL}$ carbenicillin, and 35 $\mu\text{g}/\text{mL}$ chloramphenicol) (Sigma Merck) at 37 °C and 250 RPM (New Brunswick Innova 40 shaking incubator), overnight. The following day, the starter culture was inoculated in 100 mL of fresh media at a ratio of 1:100 and grown at 37 °C and 250 RPM until the OD_{600} was between 0.5 and 0.6. The expression of recombinant GLYAT or GLYATL1 was then induced by supplementing the media with 0.05 mM IPTG, 5 g/L arabinose, and 0.2% m/v glycine or 0.2% m/v glutamine (Sigma Merck) (for GLYAT or GLYATL1, respectively), then lowering the temperature to 25 °C and leaving the cells for 24 h at 250 RPM (New Brunswick Innova 40 shaking incubator).

Thereafter, the cells were pelleted at 4,500 x g and 4 °C for 10 min, the clarified supernatant was discarded, and the cells were resuspended in 10 mL of a modified RIPA buffer (0.29% m/v NaCl, 3.6% m/v NaH_2PO_4 , 1% v/v Triton X-100)(Sigma Merck) which was supplemented to 1 U/10 mL of Pierce Universal Nuclease (Thermo Fisher Scientific). Each suspension was left on ice for 15 min before being passed through at 22-G needle 10 times. The lysate was centrifuged at 14500 x g and 4 °C for 30 min whereafter 9 mL of the clarified supernatant was removed for purification.

Protino Ni-TED 2000 (Machery-Nagel) columns were used to purify the recombinant enzymes as per the manufacturer's instructions which resulted in three 3 mL fractions. The protein concentration of each fraction was determined using a Qubit 2.0 fluorometer and the BR protein assay kit from Invitrogen according to the manufacturer's instructions. The proteins could be stored for at least four weeks at 4 °C without noticeable loss of protein or activity.

2.10. Relative enzyme activity

Microplate assays were all performed in a BioTek Synergy HT plate reader at 37 °C, 25 mM TRIS-HCl (final concentration, pH 8.13), with 0.5 μg of recombinant protein (from 10 $\mu\text{g}/\text{mL}$ stock), at 412 nm, in 100 μL volumes. Relative activities of the enzymes, in nmol/min/mg, were calculated over the first 10 min period where the reaction proceeded linearly. Stock solutions of 50 mM of benzoyl-CoA, phenylacetyl-CoA, and isovaleryl-CoA were prepared in milliQ water and stored at –20 °C until needed. Dilution ranges were prepared with milliQ water as necessary to ensure that only 5 μL of the relevant acyl-substrate were added to the reaction mix. Similarly, 100 mM stock solutions of glycine and glutamine were prepared in milliQ water, filtered through a 22 nm CA membrane, stored at 4 °C, and diluted as necessary to ensure that only 20 μL of the relevant amino acid substrate were added. A fresh 10 mM stock solution of DTNB was prepared in absolute ethanol of which 2 μL were added to the reaction mix for a final concentration of 200 μM . The volume was adjusted to 95 μL with milliQ water and the reactions were initiated with 5 μL of the recombinant enzyme.

Each assay was performed in a technical triplicate, the data were exported from the BioTek Gen5 1.11 software into an MS Excel spreadsheet, where initial data wrangling was performed before being analyzed and graphed in Wolfram™ Mathematica™ 13.0 [72]. Negative controls were set up similarly either excluding enzyme or excluding substrate. The enzyme did not meaningfully absorb at 412 nm, the acyl-CoA substrates did not spontaneously conjugate with the amino acid substrates, nor did the DTNB degrade or spontaneously conjugate with acyl-CoA or any free CoA in a manner detectable by the plate reader. Negative controls were used to blank the data. A variety of conditions were tested, and these are summarized in Table 2. The concentrations for the substrates which were kept constant were selected based on previous kinetic studies [52,73].

3. Results and discussion

In this study we proposed that GLYAT and/or GLYATL1 might be responsible for the formation of *N*-isovalerylglycine in IVA patients. To test this hypothesis, we performed an *in-silico* analysis to determine which enzyme is more likely to conjugate isovaleryl-CoA with glycine followed by an *in vitro* validation using purified enzyme preparations.

Genetic variants can affect enzyme activity. Therefore, we first analysed the variant data available on the Ensembl database (ensembl.org/) to determine the haplotype of GLYAT and GLYATL1 with the highest frequencies in the worldwide population. This was done to enzymatically characterize relevant variants of the enzymes.

Table 2
Experimental design to test the activities of GLYAT and GLYATL1 with varying substrate concentrations.

Purpose	Constant Substrate	Variable Substrate
Evaluate the baseline enzyme activity of GLYAT and GLYATL1	Preferred amino acid	Preferred acyl-CoA
Evaluate the ability of GLYAT and GLYATL1 to conjugate isovaleryl-CoA as a substrate	Preferred amino acid	Isovaleryl-CoA
Determine the correlation between amino acid concentration and GLYAT and GLYATL1 reaction rate	Preferred acyl-CoA	Preferred amino acid
Determine the correlation between amino acid concentration and GLYAT and GLYATL1 reaction rate	Isovaleryl-CoA	Preferred amino acid

Amino acid substrates, when constant, were 20 mM whereas the preferred acyl-CoA substrates (benzoyl-CoA or phenylacetyl-CoA) were 250 μ M and isovaleryl-CoA was 500 μ M. Concentration variables for the acyl-CoA substrates were: 50, 100, 250, and 500 μ M. Amino acid substrate concentrations were varied as follows: 0.5, 1, 2, 5, 10, and 20 mM.

Previous studies have shown that for GLYAT, the S₁₅₆ haplotype has the highest haplotype frequency and enzyme activity [52,73]. GLYATL1 has not been previously characterized and therefore, the wildtype reference haplotype (NM_001389712.2) with the highest haplotype frequency (97.9%) was characterized in this study.

3.1. Molecular modelling and docking

For the *in-silico* analyses, we have created three-dimensional structures of the GLYAT and GLYATL1 enzymes using SWISS-MODEL. We considered these structures reliable for docking as they satisfied most, or all of the quality parameter tests. Thereafter, we performed a molecular docking of the bi-substrate enzymes GLYAT/GLYATL1 with several substrates using AutoDock Vina. As positive controls and as known substrates for GLYAT/GLYATL1, we performed molecular docking of GLYAT to benzoyl-CoA and glycine and GLYATL1 to phenylacetyl-CoA and glutamine. We, subsequently, tested the hypothesis whether GLYAT and/or GLYATL1 can bind isovaleryl-CoA and glycine.

Secondary structure prediction from PSIPRED for GLYAT indicated 12 α -helices, 14 β -strands connected with random coils (Supplementary Figure 1). Secondary structure prediction from PSIPRED for GLYATL1 indicated 11 α -helices and 14 β -strands and connected with random coils (Supplementary Figure 2). None of the proteins had predicted disordered states (Supplementary Figures 3 and 4). However, findings from the 3D structures for GLYAT indicated 12 α -helices and 13 β -strands (Fig. 2A) and GLYATL1 indicated 13 α -helices and 12 β -strands (Fig. 2B).

Further, the 3D predicted GLYAT and GLYATL1 protein structures had high GMQE indicating that the models were of reliable quality and accuracy (Table 3). Both models passed all quality assessments including the Procheck assessment as more than 90% of the residues were within the allowable regions of the Ramachandran plot (Table 3), the VERIFY3D assessment as both protein structures had more than 80% of residues with a score of greater than 0.2 and the ERRAT assessment had scores higher than 50. ProSA analysis indicated that both structures z-scores were within the range of scores

typically found for native proteins of a similar size. Furthermore, the RMSD scores for the GLYAT/GLYATL1 proteins were less than 2 Å when compared to the homologous templates as well as the α -phafold templates suggesting high structural similarity (Table 3). In addition, we have also compared our 3D predicted GLYAT structure (S₁₅₆ haplotype of the Ref seq NM_201648.3) to a previously generated structure (NM_201648) [73]. High similarity was predicted when comparing these structures (RMSD = 0.005 Å). Therefore, our predicted 3D structures of GLYAT and GLYATL1 satisfied all the quality parameter tests and were considered for subsequent docking studies.

We analyzed the molecular docking of all substrates in two steps. First, GLYAT or GLYATL1 was docked against one substrate and the output docking complex was then used to dock the second substrate. Table 4 presents the respective docking profiles for when (1) GLYAT or GLYATL1 was docked against one substrate and (2) the output docking complex was docked against the second substrate. Therefore, Table 4, represents the interaction profile as each substrate is being docked respectively. GLYAT docked with a slightly higher affinity to benzoyl-CoA (-6.6 kcal/mol) in comparison to isovaleryl-CoA (-6.3 kcal/mol), however, the docking of glycine resulted in the same affinity for both (-4.1 kcal/mol) interactions (Table 4). The same affinity for glycine may be due to interaction with the same binding pocket in both docking interactions (Fig. 3 A and B). The docking affinity of GLYAT+isovaleryl-CoA to glutamine (-6.4 kcal/mol) was higher than that of GLYAT+isovaleryl-CoA to glycine (-4.1 kcal/mol). Interestingly, when comparing the number and type of interactions between the GLYAT benzoyl-CoA+glycine complex versus the GLYAT isovaleryl-CoA+glycine complex, the latter had a greater number of interactions of 19 compared to the former of 16 (Table 4). When comparing and profiling the number and type of interactions for the entire complex (GLYAT+both substrates) as one docking reaction, GLYAT+isovaleryl-CoA/glutamine had the greatest number of interactions (29), followed by the GLYAT+isovaleryl-CoA/glycine (25) and GLYAT+benzoyl-CoA/glycine (21) (Supplementary Table 1). Supplementary Table 1 represents the interaction profile of the entire complex (GLYAT/GLYATL1 + both substrates) and therefore




Fig. 2. 3D structure of (A) GLYAT and (B) GLYATL1. The alpha-helical structures are indicated in red, and the beta-strands are indicated in yellow. The N-terminal Met1 and C-terminal Leu296/Phe302 are shown as stick structures.

Table 3
Summary of the quality assessment scores for the 3D predicted structures of GLYAT and GLYATL1.

Enzyme	Template	GMOE	Procheck (Percentage in allowed region)	VERIFY3D	ERRAT	ProSA (z-score)	RMSD (Å)	Comparative RMSD (Å)
GLYAT	7pk1.	0.92	Pass (100%)	Pass (98.65%)	92.71	Pass (-8.69)	0.893	0.339
GLYATL1	7pk1.	0.80	Pass (100%)	Pass (100%)	86.06	Pass (-7.85)	1.148	0.488

VERIFY3D: % of the residues with a 3D–1D score > = 0.2.

Comparative analysis: RMSD when comparing generated structures and structures from the alphafold database.

presents the docking interactions after both substrates have bound. These findings are also in line with the predicted binding affinities (Table 4).

Structurally, the binding of these substrates was very similar (Fig. 3 A, B and C). GLYATL1 docked with a slightly higher affinity to phenylacetyl-CoA (-8.6 kcal/mol) compared to isovaleryl-CoA (-8.4 kcal/mol). When comparing the number and type of interactions between GLYATL1 and phenylacetyl-CoA versus GLYATL1 and isovaleryl-CoA the latter had a greater number of interactions of 19 compared to the former of 15 (Table 4). This finding is in line with the findings for GLYAT. Further, GLYATL1 + phenylacetyl-CoA docked with a higher binding affinity to glycine (-3.6 kcal/mol) compared to glutamine (-4.1 kcal/mol). On the other end, GLYATL1 + isovaleryl-CoA docked with a higher affinity to glutamine (-5.0 kcal/mol) compared to glycine (-3.5 kcal/mol) (Table 4). When comparing the number and type of interactions for the entire complex (GLYATL1 + both substrates), GLYATL1 + isovaleryl-CoA/glutamine had the greatest number of interactions (26), followed by GLYATL1 + phenylacetyl-CoA/glutamine (24), GLYATL1 + isovaleryl-CoA/glycine (23) and GLYATL1 + phenylacetyl-CoA/glycine (22) (Supplementary Table 1). Structurally, the binding was similar for all interactions with GLYATL1 (Fig. 3D-F) besides for GLYATL1 and isovaleryl-CoA/glutamine (Fig. 3G).

Our findings indicate that molecular modelling assisted in generating reliable GLYAT and GLYATL1 protein structures useful for molecular docking studies. Molecular docking suggested that GLYAT had a slightly higher affinity for benzoyl-CoA in comparison to isovaleryl-CoA, however, the docking of glycine resulted in the same affinity for both interactions, most likely due to glycine utilizing the same binding site. When glutamine is used as the amino acid substrate to the GLYAT- isovaleryl-CoA complex, the binding affinity was higher compared to when glycine was used as the amino acid substrate. This may suggest that glutamine may be the preferred amino acid substrate for isovaleryl-CoA interactions. Interestingly, the docking of GLYAT to isovaleryl-CoA and glycine/glutamine had a greater number of interactions (H-bonds, Salt bridges, π -Cation and Hydrophobic) compared to the docking of GLYAT to benzoyl-CoA and glycine, despite a lower binding affinity. This may be due to different binding sites utilized by isovaleryl-CoA compared to benzoyl-CoA (Fig. 3A versus Figures 3B and 3C) as in addition to the non-covalent intermolecular interactions that influence binding affinity, the dynamics of protein binding pockets are also crucial for their interaction specificity and affinity [74]. However, this warrants further investigation. GLYATL1 docked with a slightly higher affinity and a greater number of interactions with phenylacetyl-CoA in comparison to isovaleryl-CoA. Further, GLYATL1 docked with a higher affinity to phenylacetyl-CoA and glutamine compared to phenylacetyl-CoA and glycine. These findings support the notion that phenylacetyl-CoA and glutamine are the preferred substrates for GLYATL1 [41,48]. Similar to the findings reported for GLYAT, GLYATL1 + isovaleryl-CoA docked with a higher affinity to glutamine compared to glycine, which again questions whether glutamine may be the preferred amino acid substrate for isovaleryl-CoA interactions.

The focus of the current study was to determine whether GLYAT or GLYATL1 can conjugate isovaleryl-CoA to glycine. Therefore, the relative enzyme activity of both enzymes for their preferred

substrates were included as control reactions and compared to the ability of the enzymes to form isovalerylglycine.

3.2. Evaluation of the relative enzyme activity of GLYAT and GLYATL1 using different substrate combinations

Previous studies have shown that the preferred substrates for GLYAT is benzoyl-CoA and glycine [41,43] and for GLYATL1 it is phenylacetyl-CoA and glutamine [41,48]. We expanded on their work by testing three hypotheses. Firstly, whether GLYAT or GLYATL1 can conjugate isovaleryl-CoA to their preferred amino acid substrates (glycine and glutamine respectively). Secondly, we tested whether increasing the amino acid (glycine or glutamine) concentration increased the rate of acyl-CoA conjugation by GLYAT or GLYATL1. Thirdly, whether GLYATL1 can conjugate isovaleryl-CoA with glycine. In order to test our hypotheses, we expressed and purified human GLYAT and GLYATL1 and we performed a series of DNTB-based spectrophotometric kinetic assays as outlined in Table 2.

In this study we determined the relative enzyme activity between the ability of GLYAT to conjugate benzoyl-CoA and isovaleryl-CoA to glycine and GLYATL1 to conjugate phenylacetyl-CoA and isovaleryl-CoA to glutamine. The concentration range for benzoyl-CoA and the glycine concentration used, was chosen according to previously determined enzyme kinetic values [42,43,48,49,52,73,75–77]. The kinetic parameters for GLYATL1 have not been determined previously and therefore similar concentration ranges to those chosen for GLYAT, was used.

The benzoyl-CoA conjugation to glycine by GLYAT (Fig. 4) corresponds with previous *in vivo* and *in vitro* studies which showed that as the amount of benzoic acid (benzoyl-CoA as substrate) is increased, the formation and excretion of hippuric acid will also increase [52,78–80]. Confirming these results supports the notion that GLYAT is indeed responsible for the detoxification of benzoyl-CoA.

This is the first study to show a dose-dependent increase in reaction rate between the concentration of phenylacetyl-CoA and that of phenylacetylglutamine formed by GLYATL1 (Fig. 5). Furthermore, both GLYAT and GLYATL1 can conjugate isovaleryl-CoA with their preferred amino acid substrate (Figs. 4 and 5). However, there is no dose-dependent increase in reaction rate when isovaleryl-CoA is used as the acyl-CoA substrate. The difference in reaction rate between 500 μ M benzoyl-CoA and 500 μ M isovaleryl-CoA was more than 13-fold whereas it was nearly 42-fold with the same concentration of phenylacetyl-CoA and isovaleryl-CoA for GLYATL1. Excretion of *N*-isovalerylglycine has been mentioned in various IVA studies [81–83] with one study reporting it as 122 \pm 87 mmol/mol creatinine in urine of untreated IVA patients [82].

Therefore, while both enzymes convert isovaleryl-CoA to an isovaleryl-amino acid conjugate, the rate at which they conjugate isovaleryl-CoA is not only significantly lower than for the preferred acyl-CoA substrate, but they are also less responsive to increases in isovaleryl-CoA concentration. Additionally, these results align with the molecular docking study which indicates that the affinities of GLYAT and GLYATL1 for isovaleryl-CoA are lower than for the preferred acyl-CoA substrates (Table 4). However, the significant difference in conjugation rates does conflict with the predicted

Table 4
The interaction binding affinities and the number and type of interactions for both GLYAT and GLYATL1 docked to the respective substrates.

Protein	Substrate	Affinity (kcal/mol)	H-bonds (amino acids)	Salt bridges (Amino acids)	π -Cation (Amino acids)	Hydrophobic (Amino acids)
GLYAT	Benzoyl-CoA	-6.6 kcal/mol	TYR72, GLN103, LYS127, ARG131, HIS186, ASN190, ASP266, ASN292	HIS71, HIS71, HIS101, LYS127		GLN130, HIS186, PHE187, TYR267
GLYAT + Benzoyl-CoA	Glycine	-4.1 kcal/mol	THR75, GLN103, GLN105	ARG229		
GLYAT	Isovaleryl-CoA	-6.3 kcal/mol	TRP185, HIS186, THR233, ARG238, ARG238, ARG238, LEU239, GLY241, LEU242, VAL243, THR244, THR244, ASN269	HIS186, ARG238, ARG238		HIS186, PHE187, ALA271
GLYAT + Isovaleryl-CoA	Glycine	-4.1 kcal/mol	TYR72, GLN105, GLN105, ARG229, ARG229			
GLYAT + Isovaleryl-CoA	Glutamine	-6.4 kcal/mol	103 A, 105 A, 105 A, 224 A, 224 A, 225 A	229 A		75 A, 196 A
GLYATL1	Phenylacetyl-CoA	-8.6 kcal/mol	LYS187, LYS187, SER234, SER234, SER234, ARG239, ARG240, ASN270	239 A, 239 A	186 A, 289 A	TRP186, ALA232, TYR233
GLYATL1 + Phenylacetyl-CoA	Glutamine	-4.1 kcal/mol	GLU63, ASP66, ASP69, THR72, HIS196, ARG200, ARG200			
GLYATL1 + Phenylacetyl-CoA	Glycine	-3.6 kcal/mol	GLN104, GLN104, SER226	LYS26, ARG76		
GLYATL1	Isovaleryl-CoA	-8.4 kcal/mol	LYS187, ALA232, SER234, SER234, SER234, ARG239, ARG240, THR241, GLY242, ASN243, MET244, SER265, ASN270, SER273, SER273			TRP186, TRP186, LYS187, VAL266
GLYATL1 + Isovaleryl-CoA	Glycine	-3.5 kcal/mol	PHE40, THR72, ARG200			
GLYATL1 + Isovaleryl-CoA	Glutamine	-5.0 kcal/mol	ASP159, PHE280, GLY281	HIS157, ARG256		MET252

affinities which are only slightly lower for isovaleryl-CoA than for the preferred acyl-CoA.

Although several case studies have investigated the appropriate glycine dose to use in the treatment of IVA patients [19,26,29,84–86], no consensus has been reached due to the large interindividual variation observed. Therefore, we investigated whether increasing the amino acid (glycine or glutamine) concentration increased the rate of acyl-CoA conjugation by GLYAT or GLYATL1 (Figs. 6 and 7). The preferred acyl-CoA substrate was evaluated at 250 μ M and isovaleryl-CoA at 500 μ M. We selected a higher concentration of isovaleryl-CoA than preferred acyl-CoA given the relatively low isovaleryl-CoA conjugation rates seen in Figs. 4 and 5.

As was the case for the preferred acyl-CoA substrates, there is a dose-dependent increase in reaction rate when the preferred amino acid is used. However, in the case of GLYAT, glycine concentrations above 10 mM inhibit the reaction rate when 250 μ M of benzoyl-CoA is used (Fig. 6). Previous studies have also shown that as the glycine concentration increased, the affinity of GLYAT for benzoyl-CoA decreased [49,87]. This indicates that there is a glycine concentration range at which GLYAT functions optimally and therefore increasing the glycine concentration above this range will not result in more product being formed.

It is important to remember that GLYAT is a sigmoidal enzyme [52], which means that reaction kinetics are influenced by the concentration of both substrates used [88]. In the case of sulfo-transferases, classic Michaelis–Menten kinetics are followed over a narrow range of substrate concentrations, while some sulfo-transferases exhibit positive or negative cooperativity (allosteric sigmoidal enzyme kinetics) when studied over a wide range of substrate concentrations. *In vivo* studies have shown that the formation of hippuric acid from benzoic acid is limited by the availability of glycine [89] and the administration of exogenous glycine to rats increases the amount of hippuric acid formed [90]. However, the sigmoidal nature of GLYAT makes it extremely difficult to interpret *in vivo* studies where the concentrations of the substrates or enzyme are not known.

The glycine conjugation pathway maintains a delicate balance in CoA levels within the mitochondria [91] and glycine concentration within the mitochondria is also tightly regulated [92]. Allosteric regulation of certain enzymes evolved in order to control metabolic flow [93] by, for example, preventing the depletion of critical substrates in the mitochondria such as glycine and acyl-CoA [94]. Support for this idea may also be found in the lower binding affinities that GLYAT and GLYATL1 exhibit for their amino acid substrates (Table 4). This may be a mechanism by which acyl-CoA and amino acid homeostasis are preserved. However, a more detailed investigation of the GLYAT and GLYATL1 kinetics would be needed to better understand this.

While the conjugation of benzoyl-CoA by GLYAT appears to be slightly inhibited at 20 mM of glycine, GLYATL1 still appears responsive to glutamine concentrations of up to at least 20 mM (Fig. 7). It is difficult to interpret these values as the kinetic parameters and mechanism for GLYATL1 still needs to be elucidated. Studies have shown that liver tissue can contain up to 11 mmol/kg and 15 mmol/kg of glycine or glutamine, respectively [95]. A recent *in vitro* study has shown that cytosolic concentrations of glycine or glutamine is approximately 5 mM and 12 mM respectively [96], which are well below the amino acid concentration at which GLYAT and GLYATL1 function optimally.

Interestingly, the isovaleryl-CoA conjugation rates for GLYAT and GLYATL1 seemed largely independent of glycine and glutamine concentrations, respectively. Although GLYAT appeared to have a significant ($p < 0.05$) increase in reaction rate at 10 mM glycine (Fig. 6), GLYATL1 showed a significant ($p < 0.05$) decrease in the isovaleryl-CoA conjugation rate at 20 mM of glutamine (Fig. 7). This suggests that there might be an optimal concentration of glycine




Fig. 3. Docking pose of (A) GLYAT and benzoyl-CoA/glycine, (B) GLYAT and isovaleryl-CoA/ glycine, (C) GLYAT and isovaleryl-CoA/glutamine, (D) GLYATL1 and phenylacetyl-CoA/ glutamine and (E) GLYATL1 and phenylacetyl-CoA/glycine, (F) GLYATL1 and isovaleryl-CoA/glycine and (G) GLYATL1 and isovaleryl-CoA/glutamine.

that should be used as a supplement for IVA patients. However, further *in vivo* studies will be required to confirm this. Furthermore, the reaction rates seen here using 500 μM isovaleryl-CoA will differ when the isovaleryl-CoA concentration is changed. This apparent variability in *N*-isovalerylglycine formation rates supports previous case studies, which showed that there is a limit to the patient's capability to form *N*-isovalerylglycine even when plasma glycine concentrations are high [19,27–29,84]. This indicates that the ability of an IVA patient to metabolize isovaleryl-CoA depends on the interplay of metabolite concentrations, enzyme isoforms, and treatment regimen.

Both the variability of isovaleryl-CoA conjugation rates and the apparent insensitivity to amino acid concentrations further complicate possible treatments for IVA patients. High glycine concentrations, for example during glycine supplementation or inefficient glycine clearance, could be toxic for humans [97,98]. Glycine supplementation in some IVA patients had to be stopped because of side-effects due to hyperglycinemia [28,99]. A more recent long-term study on the neurological outcome of 80 patients with classical organic acidurias (including isovaleric acidemia) promoted glycine treatment in IVA and indicated that they did not observe any correlation between plasma glycine and neurological




Fig. 4. The acyl-CoA conjugation rate of GLYAT was tested with varying concentrations of benzoyl-CoA (green) and isovaleryl-CoA (pink) using 20 mM glycine. The reaction rate of GLYAT correlates with increases in benzoyl-CoA concentration. While there are minor fluctuations in the conjugation rate of isovaleryl-CoA, overall, it appears as if the conjugation rate is largely independent of isovaleryl concentrations at or below 500 μM . Error bars indicate the mean \pm standard deviation for triplicate assays.




Fig. 5. The conjugation rates of GLYATL1 were tested with varying phenylacetyl-CoA (green) and isovaleryl-CoA (pink) concentrations using 20 mM glutamine. The reaction rate correlates strongly with phenylacetyl-CoA concentration. Similar to GLYAT however, the isovaleryl-CoA conjugation rate appears largely insensitive to concentrations below 500 μM . Error bars indicate the mean \pm standard deviation for triplicate assays.




Fig. 6. Acyl-CoA conjugation rates for benzoyl-CoA (green) and isovaleryl-CoA (pink) against varying glycine concentrations. Assays were performed with either 250 μM benzoyl-CoA or 500 μM isovaleryl-CoA. Error bars indicate the mean \pm standard deviation for triplicate assays.

outcome. No precise therapeutic dose were however mentioned in this publication [100]. van Vliet and co-workers (2014) clearly state that a plasma glycine concentration over 1000 $\mu\text{mol/L}$ should be avoided as historical studies indicated that encephalopathy side effects were observed in dosages of 300–600 mg/kg/day [25]. For some




Fig. 7. Phenylacetyl-CoA (green) and isovaleryl-CoA (pink) conjugation rates vs. glutamine concentration. Assays were performed with either 250 μM phenylacetyl-CoA or 500 μM isovaleryl-CoA. Error bars indicate the mean \pm standard deviation for triplicate assays.

patients, monotherapy with L-carnitine may be more advantageous [9]. However, assessing the glycine conjugation capacity in patients on a combined or mono-therapeutic trial may be required in order to optimise treatment.

Finally, we tested whether GLYATL1 was able to conjugate isovaleryl-CoA with glycine because glycine is not the preferred amino acid for GLYATL1 [41]. These isovaleryl-CoA conjugation rates were then compared to the conjugation rates of GLYAT using glycine and GLYATL1 using glutamine (Fig. 8).

In Fig. 8 we can see that GLYATL1 can conjugate isovaleryl-CoA with both amino acids, albeit at a lower rate than GLYAT. The isovaleryl conjugation rates for GLYAT and GLYATL1 appear to be somewhat independent of glycine or glutamine concentrations as opposed to when the preferred acyl-CoA substrate is used. GLYATL1 is seemingly unique in its ability to conjugate benzoyl-CoA and isovaleryl-CoA with glycine whereas GLYAT appears unable to conjugate isovaleryl-CoA with glutamine (data not shown).

Given that GLYAT and GLYATL1 are co-expressed *in vivo*, it seems likely that the excreted N-isovalerylglycine observed in IVA patients is a combination of N-isovalerylglycine formed by both GLYAT and GLYATL1. One case study showed that urinary N-isovalerylglycine excretion remained at a plateau for 4 days after the highest level of plasma isovaleric acid was observed [101]. This further supports the results observed in this study as it was shown that although N-isovalerylglycine is formed, it is at a very low rate when compared to the preferred substrates. The elimination of isovaleryl-CoA in an IVA patient, may take several days especially in patients experiencing an ongoing attack.




Fig. 8. Isovaleryl-CoA conjugation rates between GLYAT and glycine (green), GLYATL1 and glycine (pink) and GLYATL1 and glutamine (orange). The amino acid concentrations were varied while the isovaleryl-CoA concentration was 500 μM . Error bars indicate the mean \pm standard deviation for triplicate assays.

4. Conclusion

Evidence from our molecular docking and enzyme kinetic studies confirm previously accepted evidence that benzoyl-CoA and glycine and phenylacetyl-CoA and glutamine are the preferred substrate pairs for GLYAT and GLYATL1 respectively. The docking evaluation of GLYAT to isovaleryl-CoA had a greater number of interactions compared to the docking of GLYAT to natural substrate, benzoyl-CoA. Additionally, we were able to show that the affinities for the amino acid substrates are moderately lower than for the acyl-CoA substrates – including the non-preferred substrate isovaleryl-CoA. Using computational docking studies in understanding enzymatic reactions remains complex and therefore validation steps such as *in vitro* enzyme activity assays were also evaluated.

The relative enzyme activity studies showed that the rate of product formation was dose dependent when the preferred substrates for GLYAT and GLYATL1 was used. GLYATL1 can form *N*-phenylacetylglutamine, *N*-isovalerylglutamine, *N*-isovalerylglycine and *N*-benzoylglycine (hippurate) while GLYAT can only form the latter two compounds. Contrary to established treatment methodologies [26,102,103], increasing glycine concentration does not appear to increase the rate at which GLYAT and GLYATL1 conjugate isovaleryl-CoA. The complex interplay between genetic variations, metabolite concentrations, dietary supplementation, and the kinetics of GLYAT and GLYATL1 likely account for the observed inter-individual variation in the amount of *N*-isovalerylglycine excreted by IVA patients.

This study furthered our understanding of the role GLYAT and GLYATL1 play in the phase II detoxification of acyl-esters of CoA. We highlight the need for activity studies of purified glycine-*N*-acyl-transferase family enzymes with a variety of acyl-CoA and amino acid substrates. Additionally, we demonstrate the value of using molecular docking studies to guide and interpret such kinetic experiments. This study contributes to not only the treatment strategy for IVA but also other branched chain amino acidurias. Limiting the other sources of substrates for GLYAT (Fig. 1), for example benzoate that results in benzoyl-CoA or benzoyl-CoA that is formed by the gut microbes, may even play a role to reduce the primary substrates of GLYAT and GLYATL1 and promote the formation of *N*-isovalerylglycine.

Role of the funding source

Funding was provided by the North-West University, South Africa. They played no role in the study design, execution of the study or the writing of this article.

CRedit authorship contribution statement

Stefan Kühn: Data curation; Formal analysis; Methodology; Validation; Visualization; Writing - original draft; Writing - review & editing. **Monray E. Williams:** Data curation; Formal analysis; Methodology; Validation; Visualization; Writing - original draft; Writing - review & editing. **Marli Dercksen:** Writing - original draft. **Jörn Oliver Sass:** Writing - review & editing. **Rencia van der Sluis:** Conceptualization; Data curation; Formal analysis; Methodology; Project administration; Resources; Supervision; Writing - original draft; Writing - review & editing.

Declaration of Competing Interest

The authors declare that there are no conflict of interest.

Acknowledgement

Research support by Heinz und Heide Dürr Stiftung (Berlin, Germany) to J.O. Sass is gratefully acknowledged. MW was funded by DSI-NRF Research Development Grants for new Generation of Academics Programme (nGAP) Scholars.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.csbj.2023.01.041.

References

- [1] Zytkevich TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. *Clin Chem* 2001;47(11):1945–55.
- [2] Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multi-analyte screening of dried blood specimens from newborns. *Clin Chem* 2003;49(11):1797–817.
- [3] Ensenauer R, Vockley J, Willard J-M, et al. A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. *Am J Hum Genet* 2004;75(6):1136–42.
- [4] Mütze U, Henze L, Gleich F, et al. Newborn screening and disease variants predict neurological outcome in isovaleric aciduria. *J Inher Metab Dis* 2021;44(4):857–70.
- [5] Conrad EH, Malherbe H, Hendriks CJ, Dercksen M, Vorster BC. An overview of benefits and challenges of rare disease biobanking in Africa, Focusing on South Africa. *Biopreservation Biobanking* 2021;19(2):143–50.
- [6] Tanaka K, Budd MA, Efron ML, Isselbacher KJ. Isovaleric acidemia: a new genetic defect of leucine metabolism. *Proc Natl Acad Sci USA* 1966;56(1):236–42. <https://doi.org/10.1073/pnas.56.1.236>
- [7] Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. *Wiley Online Libr* 2006;95–103.
- [8] Trost LC, Lemasters JJ. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. *J Pharmacol Exp Ther* 1996;278(3):1000–5.
- [9] Grünert SC, Wendel U, Lindner M, et al. Clinical and neurocognitive outcome in symptomatic isovaleric acidemia. *Orphanet J Rare Dis* 2012;7(1):1–9.
- [10] Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. *Am J Med Genet C Semin Med Genet* 2006;142c(2):95–103. <https://doi.org/10.1002/ajmg.c.30089>
- [11] Ensenauer R, Vockley J, Willard JM, et al. A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. *Am J Hum Genet* 2004;75(6):1136–42. <https://doi.org/10.1086/426318>
- [12] Schlune A, Riederer A, Mayatepek E, Ensenauer R. Aspects of newborn screening in isovaleric acidemia. *Int J Neonatal Screen* 2018;4(1):7.
- [13] Dercksen M, Duran M, IJlst L, et al. Clinical variability of isovaleric acidemia in a genetically homogeneous population. *J Inher Metab Dis* 2012;17(17):2012.
- [14] Solano AF, Leipnitz G, De Bortoli GM, et al. Induction of oxidative stress by the metabolites accumulating in isovaleric acidemia in brain cortex of young rats. *Free Radic Res* 2008;42(8):707–15. <https://doi.org/10.1080/10715760802311179>
- [15] Ribeiro CA, Balestro F, Grandó V, Wajner M. Isovaleric acid reduces Na⁺, K⁺-ATPase activity in synaptic membranes from cerebral cortex of young rats. *Cell Mol Neurobiol* 2007;27(4):529–40. <https://doi.org/10.1007/s10571-007-9143-3>
- [16] Dercksen M, IJlst L, Duran M, et al. Inhibition of N-acetylglutamate synthase by various monocarboxylic and dicarboxylic short-chain coenzyme A esters and the production of alternative glutamate esters. *Biochim Et Biophys Acta (BBA)-Mol Basis Dis* 2014;1842(12):2510–6.
- [17] Kasapkara CS, Ezgu FS, Okur I, Tümer L, Biberoglu G, Hasanoglu A. N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia. *Eur J Pediatr* 2011;170(6):799–801.
- [18] Szymańska E, Jezela-Stanek A, Bogdańska A, et al. Long term follow-up of Polish patients with isovaleric aciduria. Clinical and molecular delineation of isovaleric aciduria. *Diagnostics* 2020;10(10):738.
- [19] Naglak MC, Madsen KM, Dembure PP, Salvo R, Elsas LJ. Treatment of isovaleric acidemia with glycine supplements. *Pediatr Res* 1987;21(4):293–293.
- [20] Itoh T, Ito T, Ohba S, et al. Effect of carnitine administration on glycine metabolism in patients with isovaleric acidemia: significance of acetyl carnitine determination to estimate the proper carnitine dose. *Tohoku J Exp Med* 1996;179(2):101–9.
- [21] Tanaka K, Isselbacher KJ. The isolation and identification of N-isovalerylglycine from urine of patients with isovaleric acidemia. *J Biol Chem* 1967;242(12):2966–72.
- [22] Sweetman L, Williams JC. Part 9: Organic acids. *Branched Chain Organic Acidurias*. McGraw Hill; 2013 (<http://www.ommbid.com/>).

- [23] Tanaka K, Isselbacher KJ. The isolation and identification of N-isovalerylglycine from urine of patients with isovaleric acidemia. *J Biol Chem* 1967;242(12):2966–72.
- [24] Sweetman L, Williams JC. *Branched Chain Organic Acidurias. Metabolic and Molecular Bases of Inherited Diseases*. 8th ed. McGraw-Hill; 2001.
- [25] van Vliet D, Derks TG, van Rijn M, et al. Single amino acid supplementation in aminoacidopathies: a systematic review. *Orphanet J Rare Dis* 2014;9(1):1–14.
- [26] Chinen Y, Nakamura S, Tamashiro K, et al. Isovaleric acidemia: Therapeutic response to supplementation with glycine, l-carnitine, or both in combination and a 10-year follow-up case study. *Mol Genet Metab Rep* 2017;11:2–5. <https://doi.org/10.1016/j.ymgmr.2017.03.002>
- [27] Childs B, Nyhan WL, Borden M, Bard L, Cooke RE. Idiopathic hyperglycinemia and hyperglycinuria: a new disorder of amino acid metabolism. 1. *Pediatrics* 1961;27:522–38.
- [28] De Sousa C, Chalmers R, Stacey T, Tracey B, Weaver C, Bradley D. The response to L-carnitine and glycine therapy in isovaleric acidemia. *Eur J Pediatr* 1986;144(5):451–6.
- [29] Krieger I, Tanaka K. Therapeutic effects of glycine in isovaleric acidemia. *Pediatr Res* 1976;10(1):25–9.
- [30] Schachter D, Taggart JV. Glycine N-acylase: purification and properties. *J Biol Chem* 1954;208(1):263–75.
- [31] Naglak M, Salvo R, Madsen K, Dembure P, Elsas L. The treatment of isovaleric acidemia with glycine supplement. *Pediatr Res* 1988;07/01 1988;24(1):9–13. <https://doi.org/10.1203/00006450-198807000-00004>
- [32] Bartlett K, Gompertz D. The specificity of glycine-N-acylase and acylglycine excretion in the organic acidemias. *Biochem Med* 1974;10(1):15–23.
- [33] Del Olmo A, Calzada J, Nunez M. Benzoic acid and its derivatives as naturally occurring compounds in foods and as additives: Uses, exposure, and controversy. *Crit Rev Food Sci Nutr* 2017;57(14):3084–103. <https://doi.org/10.1080/10408398.2015.1087964>
- [34] van der Sluis R. Analyses of the genetic diversity and protein expression variation of the acyl: CoA medium-chain ligases, ACSM2A and ACSM2B. *Mol Genet Genom: MGG* 2018;293(5):1279–92. <https://doi.org/10.1007/s00438-018-1460-3>
- [35] Rechner AR, Kuhnle G, Bremner P, Hubbard GP, Moore KP, Rice-Evans CA. The metabolic fate of dietary polyphenols in humans. *Free Radic Biol Med* 2002;33(2):220–35.
- [36] Lemarie F, Beauchamp E, Legrand P, Rioux V. Revisiting the metabolism and physiological functions of caprylic acid (C8:0) with special focus on ghrelin octanoylation. *Biochimie* 2016;120:40–8. <https://doi.org/10.1016/j.biochi.2015.08.002>
- [37] Killinberg PG, Davidson ED, Webster LT. Evidence for a medium-chain fatty acid: coenzyme A ligase (adenosine monophosphate) that activates salicylate. *Mol Pharm* 1971;7:260–8.
- [38] Knights KM. Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acids. *Clin. Exp Pharmacol Physiol* 1998;25:776–82.
- [39] Nandi DL, Lucas SV, Webster Jr. LT. Benzoyl-coenzyme A:glycine N-acyltransferase and phenylacetyl-coenzyme A:glycine N-acyltransferase from bovine liver mitochondria. Purification and characterization. *J Biol Chem* 1979;254(15):7230–7.
- [40] Mitchell GA, Gauthier N, Lesimle A, Wang SP, Mamer O, Qureshi I. Hereditary and acquired diseases of acyl-coenzyme A metabolism. *Mol Genet Metab* 2008;94(1):4–15. <https://doi.org/10.1016/j.ymgme.2007.12.005>
- [41] Moldave K, Meister A. Synthesis of phenylacetylglutamine by human tissue. *J Biol Chem* 1957;229(1):463–76.
- [42] Gregersen N, Kolvraa S, Mortensen PB. Acyl-CoA: glycine N-acyltransferase: in vitro studies on the glycine conjugation of straight- and branched-chained acyl-CoA esters in human liver. *Biochem Biol* 1986;35(2):210–8.
- [43] Kelley M, Vessey D. Characterization of the acyl-CoA: Amino acid N-acyltransferases from primate liver mitochondria. *J Biochem Toxicol* 1994;9:153–8.
- [44] Nilsson A, Haanstra JR, Engqvist M, et al. Quantitative analysis of amino acid metabolism in liver cancer links glutamate excretion to nucleotide synthesis. *Proc Natl Acad Sci* 2020;117(19):10294–304. <https://doi.org/10.1073/pnas.1919250117>
- [45] Baker 2nd PR, Friederich MW, Swanson MA, et al. Variant non ketotic hyperglycinemia is caused by mutations in LIAS, BOLA3 and the novel gene GLRX5. *Brain* 2014;137(Pt 2):366–79. <https://doi.org/10.1093/brain/awt328>
- [46] Pero RW. Health consequences of catabolic synthesis of hippuric acid in humans. *Curr Clin Pharm* 2010;5(1):67–73. <https://doi.org/10.2174/157488410790410588>
- [47] Zhang H, Lang Q, Li J, et al. Molecular cloning and characterization of a novel human glycine-n-acyltransferase gene GLYATL1, which activates transcriptional activity of HSE pathway. *Int J Mol Sci* 2007;8:433–44.
- [48] Matsuo M, Terai K, Kameda N, et al. Designation of enzyme activity of glycine-N-acyltransferase family genes and depression of glycine-N-acyltransferase in human hepatocellular carcinoma. *BiochemBiophysResCommun* 2012;420(4):901–6.
- [49] van der Sluis R, Ungerer V, Nortje C, AvD A, Erasmus E. New insights into the catalytic mechanism of human glycine N-acyltransferase. *J Biochem Mol Toxicol* 2017;31(11). <https://doi.org/10.1002/jbt.21963>
- [50] Badenhorst CPS, Jooste M, van Dijk AA. Enzymatic characterization and elucidation of the catalytic mechanism of a recombinant bovine glycine N-acyltransferase. *Drug Metab Dispos* 2012;40(2):346–52.
- [51] Cárdenas ML. Understanding mechanisms of enzyme co-operativity: The importance of not being at equilibrium. *Perspect Sci* 2015/03/01 2015;4:10–6. <https://doi.org/10.1016/j.pisc.2014.12.003>
- [52] Rohwer JM, Schutte C, van der Sluis R. Functional characterisation of three glycine n-acyltransferase variants and the effect on glycine conjugation to Benzoyl-CoA. *Int J Mol Sci* 2021;22(6). <https://doi.org/10.3390/ijms22063129>
- [53] McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. *Bioinformatics* 2000;16(4):404–5. <https://doi.org/10.1093/bioinformatics/16.4.404>
- [54] Jones DT, Cozzetto D. DISOPRED3: precise disordered region predictions with annotated protein-binding activity. *Bioinformatics* 2015;31(6):857–63. <https://doi.org/10.1093/bioinformatics/btu744>
- [55] He B, Wang K, Liu Y, Xue B, Uversky VN, Dunker AK. Predicting intrinsic disorder in proteins: an overview. *Cell Res* 2009;19(8):929–49. <https://doi.org/10.1038/cr.2009.87>
- [56] Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modelling server. *Nucleic Acids Res* 2003;31(13):3381–5. <https://doi.org/10.1093/nar/gkg520>
- [57] Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res* 2018;46(W1):W296–303. <https://doi.org/10.1093/nar/gky427>
- [58] Biasini M, Bienert S, Waterhouse A, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic Acids Res*. Jul 2014;42(Web Server issue):W252–8. doi:10.1093/nar/gku340.
- [59] Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. *J Appl Crystallogr* 1993;26(2):283–91. <https://doi.org/10.1107/S0021889892009944>
- [60] Bowie JU, Lüthy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. *Science* 1991;253(5016):164–70. <https://doi.org/10.1126/science.1853201>
- [61] Lüthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. *Nature* 1992;356(6364):83–5. <https://doi.org/10.1038/356083a0>
- [62] Jain CK, Gupta M, Prasad Y, Wadhwa G, Sharma SK. Homology modeling and protein engineering of alkane monooxygenase in Burkholderia thailandensis MSMB121: in silico insights. *J Mol Model* 2014;20(7):2340. <https://doi.org/10.1007/s00894-014-2340-3>
- [63] Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. *Protein Sci* 1993;2(9):1511–9. <https://doi.org/10.1002/pro.5560020916>
- [64] Messaoudi A, Belguith H, Ben Hamida J. Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 β -lactamase. *Theor Biol Med Model* 2013;10:22. <https://doi.org/10.1186/1742-4682-10-22>
- [65] Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res* 2007;35(Web Server issue):W407–10. <https://doi.org/10.1093/nar/gkm290>
- [66] Chothia C, Lesk AM. The relation between the divergence of sequence and structure in proteins. *Embo J* 1986;5(4):823–6. <https://doi.org/10.1002/j.1460-2075.1986.tb04288.x>
- [67] Xu D, Zhang Y. Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. *Biophys J* 2011;101(10):2525–34. <https://doi.org/10.1016/j.bpj.2011.10.024>
- [68] Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* 2010;31(2):455–61. <https://doi.org/10.1002/jcc.21334>
- [69] Mawal YR, Qureshi IA. Purification to homogeneity of mitochondrial acyl coa:glycine n-acyltransferase from human liver. *Biochem Biophys Res Commun* 1994;205(2):1373–9. <https://doi.org/10.1006/bbrc.1994.2817>
- [70] Schachter D, Taggart JV. Benzoyl coenzyme A and hippurate synthesis. *J Biol Chem* 1953;203:925–34.
- [71] Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein-ligand interaction profiler. *Nucleic Acids Res* 2015;43(W1):W443–7. <https://doi.org/10.1093/nar/gkv315>
- [72] Mathematica. 2022. <https://www.wolfram.com/mathematica>.
- [73] van der Sluis R, Badenhorst CP, van der Westhuizen FH, van Dijk AA. Characterisation of the influence of genetic variations on the enzyme activity of a recombinant human glycine N-acyltransferase. *Gene* 2013;515(2):447–53. <https://doi.org/10.1016/j.gene.2012.12.003>
- [74] Stank A, Kokh DB, Fuller JC, Wade RC. Protein binding pocket dynamics. *Acc Chem Res* 2016;49(5):809–15. <https://doi.org/10.1021/acs.accounts.5b00516>
- [75] van der Westhuizen FH, Pretorius PJ, Erasmus E. The utilization of alanine, glutamic acid, and serine as amino acid substrates for glycine N-acyltransferase. *J Biochem Mol Toxicol* 2000;14(2):102–9.
- [76] Mawal YR, Qureshi IA. Purification to homogeneity of mitochondrial acyl coa:glycine n-acyltransferase from human liver. *BiochemBiophysResCommun* 1994;205(2):1373–9.
- [77] Schulke D, Sass JO. Frequent sequence variants of human glycine N-acyltransferase (GLYAT) and inborn errors of metabolism. *Biochimie* 2021. <https://doi.org/10.1016/j.biochi.2021.02.002>
- [78] Levy G. Pharmacokinetics of salicylate elimination in man. *J Pharm Sci* 1965;54(7):959–67.
- [79] Quick AJ, Cooper MA. The effect of liver injury on the conjugation of benzoic acid in the dog. *J Biol Chem* 1932;99:119–24.
- [80] Schachter D. The chemical estimation of acyl glucuronides and its application to studies on the metabolism of benzoate and salicylate in man. *J Clin Investig* 1957;36(2):297–302.
- [81] Lehnert W. Excretion of N-isovalerylglycine in isovaleric acidemia. *Clin Chim Acta* 1981;116(2):249–52. [https://doi.org/10.1016/0009-8981\(81\)90030-9](https://doi.org/10.1016/0009-8981(81)90030-9)

- [82] Dercksen M, Koekemoer G, Duran M, Wanders RJ, Mienie LJ, Reinecke CJ. Organic acid profile of isovaleric acidemia: a comprehensive metabolomics approach. *Metabolomics* 2013;9(4):765–77.
- [83] Loots DT, Erasmus E, Mienie LJ. Identification of 19 new metabolites induced by abnormal amino acid conjugation in isovaleric acidemia. *Clin Chem* 2005;51(8):1510–2.
- [84] Fries MH, Rinaldo P, Schmidt-Sommerfeld E, Jurecki E, Packman S. Isovaleric acidemia: response to a leucine load after three weeks of supplementation with glycine, L-carnitine, and combined glycine-carnitine therapy. *J Pediatr* 1996;129(3):449–52.
- [85] Cohn RM, Yudkoff M, Rothman R, Segal S. Isovaleric acidemia: use of glycine therapy in neonates. *N Engl J Med* 1978;299(18):996–9. <https://doi.org/10.1056/nejm197811022991807>
- [86] Yudkoff M, Cohn RM, Puschak R, Rothman R, Segal S. Glycine therapy in isovaleric acidemia. *J Pediatr* 1978;92(5):813–7. [https://doi.org/10.1016/s0022-3476\(78\)80164-4](https://doi.org/10.1016/s0022-3476(78)80164-4)
- [87] Dempsey DR, Bond JD, Carpenter AM, Rodriguez Ospina S, Merkler DJ. Expression, purification, and characterization of mouse glycine N-acyltransferase in *Escherichia coli*. *Protein Expr Purif* 2014;97:23–8. <https://doi.org/10.1016/j.pep.2014.02.007>
- [88] Palmer T. ENZYMES Biochemistry, Biotechnology, Clinical Chemistry. Horwood Series in Chemical Science. 5 ed. Horwood Publishing Limited; 2001. p. 402.
- [89] Knights K, Vessey D. Enzymology of amino acid conjugation reactions. *Comprehensive Toxicology*. Elsevier; 2010. p. 459–83.
- [90] Gregus Z, Fekete T, Varga F, Klaassen C. Dependence of glycine conjugation on availability of glycine: role of the glycine cleavage system. *Xenobiotica* 1993;23(2):141–53.
- [91] Badenhorst CP, van der Sluis R, Erasmus E, van Dijk AA. Glycine conjugation: importance in metabolism, the role of glycine N-acyltransferase, and factors that influence interindividual variation. *Expert Opin Drug Metab Toxicol* 2013;9(9):1139–53. <https://doi.org/10.1517/17425255.2013.796929>
- [92] Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. *Proc Jpn Acad, Ser B* 2008;84(7):246–63.
- [93] Ebrecht AC, Solamen L, Hill BL, Iglesias AA, Olsen KW, Ballicora MA. Allosteric control of substrate specificity of the *Escherichia coli* ADP-glucose pyrophosphorylase. *Front Chem* 2017;5:41. <https://doi.org/10.3389/fchem.2017.00041>
- [94] Badenhorst CP, Erasmus E, van der Sluis R, Nortje C, van Dijk AA. A new perspective on the importance of glycine conjugation in the metabolism of aromatic acids. *Drug Metab Rev* 2014;46(3):343–61. <https://doi.org/10.3109/03602532.2014.908903>
- [95] Barle BA H, Nyberg B, Andersson K, Essén P, Wernerman J. The concentrations of free amino acids in human liver tissue obtained during laparoscopic surgery. *Clin Physiol* 1996;16(3):217–27.
- [96] Gauthier-Coles G, Vennitti J, Zhang Z, et al. Quantitative modelling of amino acid transport and homeostasis in mammalian cells. *Nat Commun* 2021;12(1):5282. <https://doi.org/10.1038/s41467-021-25563-x>
- [97] Sandfeldt L, Riddez L, Rajs J, Ewaldsson C, Piros D, Hahn RG. High-dose intravenous infusion of irrigating fluids containing glycine and mannitol in the pig. *J Surg Res* 2001;95(2):114–25. <https://doi.org/10.1006/jsre.2000.6028>
- [98] Garlick PJ. The nature of human hazards associated with excessive intake of amino acids. *J Nutr* 2004;134(6):1633S–9S. <https://doi.org/10.1093/jn/134.6.1633S>
- [99] Berry GT, Yudkoff M, Segal S. Isovaleric acidemia: medical and neurodevelopmental effects of long-term therapy. *J Pediatr* 1988;113(1):58–64.
- [100] Nizon M, Ottolenghi C, Valayannopoulos V, et al. Long-term neurological outcome of a cohort of 80 patients with classical organic acidurias. *Orphanet J Rare Dis* 2013;8(1):1–12.
- [101] Shigematsu Y, Sudo M, Momoi T, Inoue Y, Suzuki Y, Kameyama J. Changing plasma and urinary organic acid levels in a patient with isovaleric acidemia during an attack. *Pediatr Res* 1982;16(9):771–5.
- [102] Naglak MC, Madsen KM, Dembure PP, Salvo R, Elsas LJ. Treatment of isovaleric acidemia with glycine supplements. *Pediatr Res* 1987;21:293.
- [103] Fries MH, Ronaldo P, Schmidt-Sommerfeld E, Jurecki E, Packman S. Isovaleric acidemia: response to a leucine load after three weeks of supplementation with glycine, L-carnitine, and combined glycine-carnitine therapy. *J Pediatr* 1996;129(3):449–52.